Clinical

Dr Fonesca provides his final thoughts recapping data and findings presented at ASH 2023.

Dr Fonesca highlights key factors in multiple myeloma treatment affecting patient quality of life.

A key opinion leader explores the integration of bispecifics into MM therapy regimens.

The MonumenTAL-2 study is discussed by Rafael Fonesca, MD.

The IsKia trial findings presented at ASH 2023 are highlighted by Dr Fonseca.

A medical expert navigates the treatment landscape for patients newly diagnosed with multiple myeloma.

Rafael Fonseca, MD, discusses findings from the PERSEUS trial presented in December at ASH 2023.

Key opinion leaders explore the necessary synergy between payors and providers for optimizing bispecific therapy.

Financial considerations in bispecific therapy are discussed.

Patients admitted to the hospital with acute decompensated heart failure (ADHF) who also had low muscle mass and hypoalbuminemia experienced a heightened mortality risk, suggesting skeletal muscle mass and serum albumin are important prognostic factors.

The data search of Web of Science Core Collection, spanning 2003 to 2022, identified various prospective directions in myasthenia gravis (MG) research, including in personalized treatment, subtype-based treatment, and novel immunotherapeutic strategies.

The authors suggest the phenomenon of 2 mutationally distinct diffuse large B-cell lymphomas (DLBCLs) might be more common than currently understood.

US women in low-income regions are experiencing a steep increase in cervical cancer diagnosis and death despite medical improvements; a Senate committee launches an assisted living examination, its first hearing on the industry in 2 decades; the CDC urges health care providers to be alert for patients who have fever, rashes, an traveled abroad following reports of 23 measles cases since December 1.

The phase 3 ASCERTAIN study found that orally administered decitabine and cedazuridine had similar pharmacologic effects compared with intravenously administered decitabine.

The critical impact of respiratory and physical therapists in the management of bronchiectasis is emphasized.

Pulling data from a US electronic health record–based database, researchers found low rates of complete remission and poor overall survival among 382 patients who had myelodysplastic syndromes (MDS) receiving first-line azacytidine (AZA).

Experts discuss how they determine whether a patient with metastatic breast cancer is a candidate for treatment with elacestrant based on FDA approved indication, NCCN guidelines, and the results of ESR1 mutation and resistance marker testing. Participants also discuss how they determine treatment failure or resistance.

Investigators say attempts to overcome mutational resistance to Bruton’s tyrosine kinase (BTK) inhibitors have had mixed results among patients who have chronic lymphocytic leukemia (CLL).

Researchers found TET2 clonal hematopoiesis of indeterminate potential (CHIP) to be an independent risk factor associated with incident heart failure with preserved ejection fraction (HFpEF).

The expanded indication makes dupilumab the only approved treatment for eosinophilic esophagitis (EoE) in this age group.

Dupilumab shows long-term efficacy across yearly seasons in patients with type 2 inflammatory asthma.

A record 21.3 million people signed up for health insurance this year using the Affordable Care Act (ACA) marketplaces; nearly 80% of health care providers think it is important for their hospital to minimize its environmental impact; the FDA noted a potential link between CAR-T products and the development of T-cell cancer.

A predictive model utilizing serum metabolic profiles was able to distinguish ovarian cancer from control samples with 93% accuracy, according to a new study.

Richard Adler, MD, FACS, provides perspective on AAO 2023 data suggesting dual mechanism treatment targeting aqueous deficiency and meibomian gland dysfunction may improve dry eye symptoms more significantly and faster than singular therapies, benefiting patient compliance and disease management.

Richard Adler, MD, FACS, provides insights on data presented at AA0 2023, from a study comparing results of the ARMOR procedure versus treatment with cyclosporine ophthalmic emulsion 0.05% in patients with dry eye disease.